Company Description
Biogen IDEC Inc.. The Group's principal activity is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The Group's two commercial products, Rituxan ...
Related Business Topics
Breaking News
Reuters - November 10, 2009 3:25 PM
http://www.zacks.com/ CHICAGO--(Business Wire)-- Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE: ACL), Novartis (NYSE: NVS), Gilead Sciences (Nasdaq: GILD), ...
Reuters - November 10, 2009 2:39 PM
CAMBRIDGE, MASS.--(Business Wire)-- Biogen Idec Inc. (NASDAQ/BIIB) announced today that its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference will be webcast live, via the internet, on Tuesday, November 17, 2009 at 10:55a.m. ...
Reuters - November 09, 2009 3:58 PM
CAMBRIDGE, Mass.--(Business Wire)-- Biogen Idec Inc. (NASDAQ:BIIB) announced today that its presentation at the 2009 Annual Credit Suisse Healthcare Conference will be webcast live via the internet, on Friday, November 13, 2009 at 8:30 a.m. MST, 6:30 ...
CNBC - November 09, 2009 2:58 PM
Forbes.com - November 07, 2009 8:03 AM
DUBLIN, Nov 7 (Reuters) - Ireland's Elan and U.S. drugmaker Biogen Idec have amended the label of their multiple sclerosis drug Tysabri to reflect the increased risk of contracting a potentially deadly brain infection, Elan said in a statement on ...
